November 27, 2005
Waukesha, Wisc., - GE Healthcare has announced an important new leadership position for one of the largest and fastest growing businesses within the
company. Jean-Luc Vanderheyden, a former professor and research and development executive, has been hired to the newly created position of Leader for the company's Molecular Imaging business. In this new role, Vanderheyden will help in the design and development of the businesses global molecular imaging strategy, especially as it relates to integrated offerings to and partnerships with academic institutions.

"GE is fortunate to work with academic and luminary leaders whose vision promises to expand the frontier of molecular imaging," said Vanderheyden. "I am very excited to sharpen the focus on GE's collaborative research with the molecular imaging community and to continue driving GE's technological leadership in molecular imaging."
In his new role, Vanderheyden will report to the General Manager of GE's Molecular Imaging business, to be named at a later date.

"This new role to help design and develop molecular imaging strategies and research collaborations will further strengthen our focus on serving our luminary customers, and enhance our commitment to support the kinds of clinical research and innovation that have made GE the industry leader in molecular imaging," said Bill Clarke, Chief Technology and Medical Officer for GE Healthcare. "I look forward to collaborating with Jean-Luc as he works with the hundreds of scientists, radiologists and engineers in the molecular imaging community who help GE continue to bring breakthrough technology to clinicians around the globe."

Prior to his new role as Molecular Imaging Leader Vanderheyden was the Vice President of Research and Development for Theseus Imaging Corporation in Boston where he designed and led the execution of a novel apoptosis imaging agent that reached phase II clinical studies. Previous to that, Vanderheyden was the Director of Nuclear Medicine Research and Development for Mallinckrodt/Tyco Healthcare. He was also a Visiting Associate Professor in Nuclear Medicine at University of Massachusetts Medical School.

Vanderheyden holds a PhD in chemistry from the University of Cincinnati, is a pharmacist, and graduated from the Universit Libre of Brussels, Belgium. He holds 10 patents in the field of radiodiagnostic and therapeutics and has 47 professional publications to his name.

Back to HCB News

More Voices